Facebook Twitter YouTube SoundCloud RSS

Academic Study: ‘Mild COVID-19 Induces Lasting Antibody Protection’ in Bone Marrow for Natural Immunity Support


Remember all those PCR positive COVID tests in early 2020? Most people who had mild to no symptoms were still forced to lock down in their homes and shut down their businesses. Even healthy people with a positive test were told to quarantine and henceforth labeled as a case. The case numbers racked up quickly and were broadcast on blast 24/7 in the news media. Public health officials and political leaders declared an endless raft of restrictive policies by fiat. Social and economic calamity followed.

That case meter runs continuously to this day. It can be dialed up or down at any time to fit the pandemic policy du jour. It’s a vicious cycle we’re stuck in. We’re also told our ‘only way out’ is vaccine immunity.

But what if those people testing positive with mild to no symptoms cleared the virus from their bodies within a few weeks and acquired long-lasting immunity?

Such a finding would obliterate the prevailing narrative force-fed to the public that pandemic policies have been worth it from the beginning because they help ‘keep us all safe.’

Washington University School of Medicine in St. Louis researchers wanted to find out whether people, months after recovering from ‘mild’ cases of COVID-19, could still produce antibodies and be provided protection against SARS-CoV-2 long after infection.

Their findings were published May 24 in the journal Nature, abstract:

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

“Long-lived bone marrow plasma cells (BMPCs) are a persistent and essential source of protective antibodies1,2,3,4,5,6,7. Individuals who have recovered from COVID-19 have a substantially lower risk of reinfection with SARS-CoV-28,9,10. Nonetheless, it has been reported that levels of anti-SARS-CoV-2 serum antibodies decrease rapidly in the first few months after infection, raising concerns that long-lived BMPCs may not be generated and humoral immunity against SARS-CoV-2 may be short-lived11,12,13. Here we show that in convalescent individuals who had experienced mild SARS-CoV-2 infections (n = 77), levels of serum anti-SARS-CoV-2 spike protein (S) antibodies declined rapidly in the first 4 months after infection and then more gradually over the following 7 months, remaining detectable at least 11 months after infection. Anti-S antibody titres correlated with the frequency of S-specific plasma cells in bone marrow aspirates from 18 individuals who had recovered from COVID-19 at 7 to 8 months after infection. S-specific BMPCs were not detected in aspirates from 11 healthy individuals with no history of SARS-CoV-2 infection. We show that S-binding BMPCs are quiescent, which suggests that they are part of a stable compartment. Consistently, circulating resting memory B cells directed against SARS-CoV-2 S were detected in the convalescent individuals. Overall, our results indicate that mild infection with SARS-CoV-2 induces robust antigen-specific, long-lived humoral immune memory in humans.”

According to senior author Ali Ellebedy, PhD, an associate professor of pathology & immunology, of medicine and of molecular microbiology, researchers looked at the bone marrow of participants to determine whether there were ‘long-lived’ plasma cells that produce the antibodies targeting SARS-CoV-2.

Once these plasma cells take up residence in the bone marrow, they provide long-lasting protection by secreting antibodies into the bloodstream that help with future encounters with the virus.

“These cells are not dividing. They are quiescent, just sitting in the bone marrow and secreting antibodies. They have been doing that ever since the infection resolved, and they will continue doing that indefinitely,” Ellebedy said, adding:

“Last fall, there were reports that antibodies wane quickly after infection with the virus that causes COVID-19, and mainstream media interpreted that to mean that immunity was not long-lived. But that’s a misinterpretation of the data. It’s normal for antibody levels to go down after acute infection, but they don’t go down to zero; they plateau. Here, we found antibody-producing cells in people 11 months after first symptoms. These cells will live and produce antibodies for the rest of people’s lives. That’s strong evidence for long-lasting immunity.”

Ever since talk of a ‘miracle’ vaccine began back in April 2020, and fast-forward to today as the experimental shots are being mandated, there has been a consistent and coordinated effort by government officials, the media and their Big Pharma backers to erase any reference to science-based natural immunity – instead claiming that the only reliable immunity in a pandemic is synthetic immunity.

The WUSTL study on natural immunity and COVID-19 is just one of 29 studies on the subject compiled in a collection here that you can share with family, friends, co-workers, employers, public health officials and politicians.

READ MORE COVID NEWS AT: 21st Century Wire COVID Files




Get Your Copy of New Dawn Magazine #203 - Mar-Apr Issue
Get Your Copy of New Dawn Magazine #203 - Mar-Apr Issue